Christoph Funk

Cholestatic Potential of Troglitazone as a Possible Factor Contributing to Troglitazone-Induced Hepatotoxicity: In Vivo and in Vitro Interaction at the Canalicular Bile Salt Export Pump (Bsep) in the Rat

Christoph Funk, Christiane Ponelle, Gerd Scheuermann et al. · Molecular Pharmacology · 2001 · 290 citations

Medicine, Pharmacokinetics, Pharmacology +17

Substrate-Dependent Drug-Drug Interactions between Gemfibrozil, Fluvastatin and Other Organic Anion-Transporting Peptide (OATP) Substrates on OATP1B1, OATP2B1, and OATP1B3

Johannes Noé, Renée Portmann, Marie-Elise Brun et al. · Drug Metabolism and Disposition · 2007 · 289 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Multi-organ system for the evaluation of efficacy and off-target toxicity of anticancer therapeutics

Christopher W. McAleer, Christopher J. Long, Daniel Elbrecht et al. · Science Translational Medicine · 2019 · 180 citations

Medicine, Oncology, Pharmacology +17

Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate

Christoph Funk · Toxicology · 2001 · 173 citations · Full text

Medicine, Biochemistry, Pharmacology +17

Variability in P-Glycoprotein Inhibitory Potency (IC50) Using Various in Vitro Experimental Systems: Implications for Universal Digoxin Drug-Drug Interaction Risk Assessment Decision Criteria

Joe Bentz, Michael O′Connor, Dallas Bednarczyk et al. · Drug Metabolism and Disposition · 2013 · 150 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +9